EurekaMag.com logo
+ Site Statistics
References:
53,869,633
Abstracts:
29,686,251
+ Search Articles
+ Subscribe to Site Feeds
EurekaMag Most Shared ContentMost Shared
EurekaMag PDF Full Text ContentPDF Full Text
+ PDF Full Text
Request PDF Full TextRequest PDF Full Text
+ Follow Us
Follow on FacebookFollow on Facebook
Follow on TwitterFollow on Twitter
Follow on LinkedInFollow on LinkedIn

+ Translate

Mycophenolate mofetil and cyclosporine in the treatment of steroid-dependent nephrotic syndrome with frequent relapses



Mycophenolate mofetil and cyclosporine in the treatment of steroid-dependent nephrotic syndrome with frequent relapses



Anales de Pediatria 69(3): 258-262



We describe the case of an 8-year-old patient, with steroid-dependent minimal lesion nephrotic syndrome, with frequent relapses despite treatment with cyclosporine. After the switch to mycophenolate mofetil the patient had new relapses, and there was difficulty in controlling the disease. The reintroduction of cyclosporine combined with mycophenolate mofetil obtained an optimal response, with a longer relapse-free time. Due to their kinetic variability, the blood levels of both drugs were closely monitored during follow-up.

(PDF emailed within 1 workday: $29.90)

Accession: 054519180

Download citation: RISBibTeXText

PMID: 18775272



Related references

Mycophenolate mofetil in steroid/cyclosporine-dependent/resistant nephrotic syndrome. Pediatric Nephrology 20(7): 914-919, 2005

Should mycophenolate mofetil be administered prior to cyclosporine A as a steroid-sparing agent to children with steroid-dependent nephrotic syndrome?. Pediatric Nephrology, 2018

The Value of Monitoring the Serum Concentration of Mycophenolate Mofetil in Children with Steroid-Dependent/Frequent Relapsing Nephrotic Syndrome. Nephron 132(4): 327-334, 2016

Cyclosporine versus mycophenolate mofetil for maintenance of remission of steroid-dependent nephrotic syndrome after a single infusion of rituximab. European Journal of Pediatrics 172(4): 513-518, 2013

Positive role of rituximab in switching from cyclosporine to mycophenolate mofetil for children with high-dose steroid-dependent nephrotic syndrome. Pediatric Nephrology 30(4): 687-691, 2015

Mycophenolate mofetil therapy for childhood-onset steroid dependent nephrotic syndrome after long-term cyclosporine: extended experience in a single center. Clinical Nephrology 72(4): 268-273, 2009

Multicenter trial of mycophenolate mofetil in children with steroid dependent or frequent relapsing nephrotic syndrome Report of the Southwest Pediatric Nephrology Study Group. Journal of the American Society of Nephrology 14(Abstracts Issue): 751A, November, 2003

Mycophenolate mofetil in treatment of childhood steroid-dependent nephrotic syndrome. La Tunisie Medicale 94(3): 221-225, 2016

Treatment with mycophenolate mofetil and prednisolone for steroid-dependent nephrotic syndrome. Pediatric Nephrology 22(12): 2059-2065, 2007

Treatment of steroid-dependent minimal change-nephrotic syndrome with mycophenolate mofetil. Nefrologia 24(1): 79-82, 2004

Mycophenolate mofetil (MMF) as the first choice immunosuppressive drug in treatment of steroid-dependent nephrotic syndrome in children. Polski Merkuriusz Lekarski 44(262): 192-195, 2018

Mycophenolate mofetil treatment in primary glomerular disease: one-year follow-up in steroid dependent and resistant nephrotic syndrome. Journal of the Medical Association of Thailand 89 Suppl 2(): S218-S227, 2006

Risk of persistent steroid dependency after switching from cyclosporine to mycophenolate mofetil in children with idiopathic nephrotic syndrome. Pediatric Nephrology 30(11): 2051-2052, 2016

Mycophenolate mofetil allows steroid withdrawal in steroid dependent nephrotic syndrome. Pediatric Research 51(4 Part 2): 429A, April, 2002

A prospective study on the use of mycophenolate mofetil in children with cyclosporine-dependent nephrotic syndrome. Pediatric Nephrology 22(1): 71-76, 2006